Spectral Medical Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Chris Seto

Chief Executive Officer (CEO)

CA$754.3k

Compensación total

Porcentaje del salario del CEO	61.2%
Permanencia del CEO	3.4yrs
Participación del CEO	0.4%
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	3.3yrs

Actualizaciones recientes de la dirección

Recent updates

We're Keeping An Eye On Spectral Medical's (TSE:EDT) Cash Burn Rate

Feb 12

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Chris Seto en comparación con los beneficios de Spectral Medical?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	n/a	n/a	-CA$19m
Mar 31 2024	n/a	n/a	-CA$19m
Dec 31 2023	CA$754k	CA$462k	-CA$16m
Sep 30 2023	n/a	n/a	-CA$10m
Jun 30 2023	n/a	n/a	-CA$9m
Mar 31 2023	n/a	n/a	-CA$7m
Dec 31 2022	CA$901k	CA$457k	-CA$8m
Sep 30 2022	n/a	n/a	-CA$7m
Jun 30 2022	n/a	n/a	-CA$7m
Mar 31 2022	n/a	n/a	-CA$7m
Dec 31 2021	CA$883k	CA$419k	-CA$7m
Sep 30 2021	n/a	n/a	-CA$8m
Jun 30 2021	n/a	n/a	-CA$8m
Mar 31 2021	n/a	n/a	-CA$7m
Dec 31 2020	CA$590k	CA$338k	-CA$9m
Sep 30 2020	n/a	n/a	-CA$8m
Jun 30 2020	n/a	n/a	-CA$8m
Mar 31 2020	n/a	n/a	-CA$7m
Dec 31 2019	CA$391k	CA$139k	-CA$5m

Compensación vs. Mercado: La compensación total de Chris($USD549.87K) está por encima de la media de empresas de tamaño similar en el mercado Canadian ($USD175.38K).

Compensación vs. Ingresos: La compensación de Chris ha sido consistente con los resultados de la empresa en el último año.

CEO

Chris Seto

3.4yrs

Permanencia

CA$754,295

Compensación

Mr. Christopher Seto, also known as Chris, serves as Chief Financial Officer, Chief Executive Officer and Director for Spectral Medical Inc. since December 01, 2023, November 12, 2021 and April 01, 2021 re...

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Christopher Seto	CEO, CFO & Director	2.8yrs	CA$754.30k	0.41% CA$ 675.6k
Paul Walker	Independent Chairman of the Board	23.4yrs	CA$103.13k	0.65% CA$ 1.1m
Janelle D'Alvise	Independent Director	3.3yrs	CA$122.02k	sin datos
David Feigal	Independent Director	1.3yrs	CA$89.27k	sin datos
William Stevens	Independent Director	10yrs	CA$114.25k	0.31% CA$ 505.6k
Cristiano Franzi	Independent Director	less than a year	sin datos	sin datos
Jun Hayakawa	Independent Director	6.3yrs	sin datos	sin datos

3.3yrs

Permanencia media

71yo

Promedio de edad

Junta con experiencia: La junta directiva de EDT se considera experimentada (3 años de antigüedad promedio).

Spectral Medical Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Independent Chairman of the Board recently sold CA$98k worth of stock

Independent Chairman of the Board exercised options to buy CA$102k worth of stock.

Less than half of directors are independent

Spectral Medical Inc. Announces Board Changes

Spectral Medical Inc., Annual General Meeting, Jun 07, 2024

Spectral Medical Inc. Announces Executive Changes

Recent updates

Independent Chairman of the Board recently sold CA$98k worth of stock

Spectral Medical Inc. Provides August Tigris Trial Update

Second quarter 2024 earnings released: CA$0.016 loss per share (vs CA$0.014 loss in 2Q 2023)

Spectral Medical Inc Provides July Tigris Trial Update

Spectral Medical Inc. announced that it has received $1 million in funding

Spectral Medical Inc. announced that it expects to receive $1 million in funding

Spectral Medical Inc. Provides June Tigris Trial Update

Independent Chairman of the Board exercised options to buy CA$102k worth of stock.

Spectral Medical Inc. announced that it has received CAD 8.499564 million in funding

First quarter 2024 earnings released: CA$0.015 loss per share (vs CA$0.006 loss in 1Q 2023)

Spectral Medical Inc. announced that it expects to receive CAD 8.499564 million in funding

Spectral Medical Inc. Provides Tigris Trial Update

Spectral Medical Provides Tigris Trial Update

Less than half of directors are independent

Price target increased by 13% to CA$1.80

Spectral Medical Inc. Announces Board Changes

Full year 2023 earnings: EPS and revenues miss analyst expectations

Spectral Medical Inc., Annual General Meeting, Jun 07, 2024

New minor risk - Market cap size

Spectral Medical Inc. Provides Update on the Company's Tigris Trial

Spectral Medical Announces Major Milestone by Reaching Its Interim Enrollment Target of 90 Patients

Spectral Medical Inc. Provides Early February Tigris Trial Update

Spectral Medical Provides January Tigris Trial Update

Spectral Medical Inc. l Enrolls Patient 82 in Its Phase 3 FDA Tigris Septic Shock Trial

Spectral Medical Inc. Provides November Tigris Trial Update

Spectral Medical Inc. Announces Executive Changes

Spectral Medical Inc. Announces Executive Changes

Spectral Medical Inc. Announces Publication of Tigris Trial Methods Paper

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Spectral Medical Provides Tigris Trial Update

New minor risk - Shareholder dilution

Spectral Medical Inc. announced that it has received CAD 6.217075 million in funding

Spectral Medical Inc. announced that it expects to receive CAD 5 million in funding from Paradigm Capital Inc.

Second quarter 2023 earnings released: CA$0.014 loss per share (vs CA$0.011 loss in 2Q 2022)

Spectral Medical Inc. Announces Tigris Clinical Trial Update

Spectral Medical Inc. Appoints David W. Feigal to Its Board of Directors

Spectral Medical Inc. Provides Update on Continued Favorable Tigris Clinical Trial Enrollment

Spectral Medical Inc. Provides Update on Favorable Tigris Clinical Trial Enrollment

Consensus revenue estimates increase by 186%

Consensus revenue estimates decrease by 61%, EPS upgraded

First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Spectral Medical Inc. Announces Resignation of Jim Funk as Director

No longer forecast to breakeven

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Spectral Medical Inc. Provides Update on Tigris Clinical Trial

Consensus forecasts updated

Consensus forecasts updated

Price target decreased to CA$2.10

Forecast to breakeven in 2024

Spectral Medical Inc. announced that it has received CAD 6.8364 million in funding

Spectral Medical Inc. announced that it expects to receive CAD 8.5 million in funding

Spectral Medical Inc. announced that it expects to receive CAD 8.5 million in funding

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Spectral Medical Provides Update on Tigris Clinical Trial

US FDA Grants Spectral Medical Breakthrough Device Designation for Toraymyxin™ for the Treatment of Endotoxemic Septic Shock

Spectral Medical Inc. Elects James Funk as Director

Spectral Medical Inc. Appoints Sam Amory as Dialco, President

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Price target decreased to CA$2.10

Forecast breakeven date pushed back to 2024

Consensus revenue estimates fall by 44%

Spectral Medical Inc., Annual General Meeting, Jun 09, 2022

Spectral Medical Inc. Through Its Wholly-Owned Subsidiary Dialco Medical Inc. Provides Clinical Trial Update on Tigris, A Follow on Study Designed to Build on Knowledge Gained from the Earlier Euphrates Trial

We're Keeping An Eye On Spectral Medical's (TSE:EDT) Cash Burn Rate

Forecast to breakeven in 2023

Third quarter 2021 earnings released: CA$0.008 loss per share (vs CA$0.007 loss in 3Q 2020)

Price target decreased to CA$2.85

Independent Chairman of the Board recently bought CA$180k worth of stock